Assessing the effect of Adjunctive probiotics therapy for the treatment of primary hypertension in children and adolescents: A randomized, double- blind, placebo- controlled trial
Phase 3
Recruiting
- Conditions
- Essential (primary) hypertension.Essential (primary) hypertension
- Registration Number
- IRCT20200608047689N3
- Lead Sponsor
- Rasht University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 110
Inclusion Criteria
Essential high blood pressure I and II
Age range between 7-18 years
Exclusion Criteria
Active infection
Known organ damage
Use of probiotics in the 3 months prior to the study
Previous history of sensitivity to probiotics
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie probiotic effects on pediatric primary hypertension pathophysiology?
How does adjunctive probiotic therapy compare to standard antihypertensive treatments in adolescents with essential hypertension?
Which biomarkers correlate with probiotic-induced blood pressure changes in IRCT20200608047689N3 pediatric participants?
What adverse events are associated with long-term probiotic use in children with primary hypertension and how are they managed?
Are there synergistic effects when combining probiotics with ACE inhibitors or calcium channel blockers for pediatric hypertension management?